Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06670222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later across 2 updates Jul 2026 → Oct 24, 2026
See other at-risk trials from Groupe Francophone des Myelodysplasies

Record History

  1. Primary completion pushed from Aug 24, 2026 to Oct 24, 2026v6
  2. Primary completion pushed from Jul 2026 to Aug 24, 2026
    • Site details revised at 2 of 3 sites
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2025 to Jul 22, 2025
    • Site details revised at 3 of 3 sites
    v4
  4. Start date: May 2025 to Jul 2025
    • Primary completion date: Jun 2026 to Jul 2026
    • Study completion date: Jun 2027 to Jul 2027
    • Site contacts updated at 3 of 3 sites
    v3
  5. Start date: Feb 2025 to May 2025
    • Primary completion date: Mar 2026 to Jun 2026
    • Study completion date: Mar 2027 to Jun 2027
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).
Trial Details
NCT Number NCT06670222
Lead Sponsor Groupe Francophone des Myelodysplasies
Conditions
(from sponsor)		 Low-risk Myelodysplastic Syndromes
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov